25 Results for "

Fucosyltransferase8

" in MedChemExpress (MCE) Product Catalog:
Products (25)

25 Results for "Fucosyltransferase8" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-E70157
Synonyms: EC:2.4.1.68; FUT8; α1-6FucT
Fucosyltransferase 8 (EC:2.4.1.68; FUT8; α1-6FucT) is a glycosyl transferase and catalyzes the transfer of a fucose residue from GDP-fucose to the innermost N-acetylglucosamine residue of N-glycans .
loading...
    loading...
Cat. No.: HY-P99113A

Target:  

CD19

Inebilizumab (FUT8-KO) is an anti-CD19 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.Inebilizumab (FUT8-KO) exhibits enhanced ADCC against B cells and can be used for research on multiple sclerosis and neuromyelitis optica .
loading...
    loading...
Cat. No.: HY-P99010A

Research Areas:  

Cancer

Bemarituzumab (FUT8-KO) is an anti-FGFR2b monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa .
loading...
    loading...
Cat. No.: HY-P9977A

Target:  

EGFR

Research Areas:  

Cancer

Amivantamab (FUT8-KO) is an anti-EGFR-MET monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Amivantamab (FUT8-KO) inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .
loading...
    loading...
Cat. No.: HY-P99406A

Target:  

EGFR

Research Areas:  

Cancer

Petosemtamab (FUT8-KO) is an anti-EGFR and anti-LGR5 monoclonal antibody expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucosyl loss enhances the ADCC effect of the antibody. Petosemtamab (FUT8-KO) leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab (FUT8-KO) can be used for research on solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC) .
loading...
    loading...
Cat. No.: HY-P99653A
Synonyms: VAY-736 (FUT8-KO)

Research Areas:  

Inflammation/Immunology Cancer

Ianalumab (VAY-736) (FUT8-KO) is an anti-BAFF-R monoclonal antibody expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose depletion enhances its B cell clearance capacity. Ianalumab (FUT8-KO) competitively blocks the binding of BAFF to BAFF-R, inhibits the BAFF-mediated alternative NF-κB pro-survival signaling pathway, and abrogates the apoptotic (apoptosis) protective effect of BAFF on cancer cells. Ianalumab (FUT8-KO) can be used in research related to primary Sjögren's syndrome and chronic lymphocytic leukemia .
loading...
    loading...
Cat. No.: HY-P9980A
Research Areas:  

Cancer

Belantamab (FUT8-KO) is an anti-BCMA (TNFRSF17) monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Belantamab (FUT8-KO) can be used to synthesize antibody-active molecule conjugate (ADC), Belantamab mafodotin .
loading...
    loading...
Cat. No.: HY-P99295A
Synonyms: RG 7160 (FUT8-KO); RO 5083945 (FUT8-KO); Anti-EGFR Recombinant Antibody (FUT8-KO)

Target:  

EGFR

Research Areas:  

Cancer

Imgatuzumab (FUT8-KO) is a humanized monoclonal antibody against EGFR expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Imgatuzumab is an immunomodulator. Imgatuzumab may be used in cancer research.
loading...
    loading...
Cat. No.: HY-P75181
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: FUT8; Fucosyltransferase 8 (Alpha (1,6) Fucosyltransferase); Fucosyltransferase 8; Alpha1-6FucT; GDP-L-Fuc:N-Acetyl-Beta-D-Glucosaminide Alpha1,6-Fucosyltransferase; Alpha (1,6) Fucosyltransferase; GDP-Fucose--Glycoprotein Fucosyltransferase; FUT8 Protein
Species:  
Human
Source:  
Sf9 insect cells
loading...
    loading...
Cat. No.: HY-P75783
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: FUT8; Fucosyltransferase 8 (Alpha (1,6) Fucosyltransferase); Fucosyltransferase 8; Alpha1-6FucT; GDP-L-Fuc:N-Acetyl-Beta-D-Glucosaminide Alpha1,6-Fucosyltransferase; Alpha (1,6) Fucosyltransferase; GDP-Fucose--Glycoprotein Fucosyltransferase; FUT8 Protein
Species:  
Others
Source:  
Sf9 insect cells
loading...
    loading...
Cat. No.: HY-P9991A

Target:  

Gap Junction Protein

Research Areas:  

Cancer

Osemitamab (FUT8-KO) is an anti-claudin-18.2 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
loading...
    loading...
Cat. No.: HY-P990755A

Target:  

EGFR

Research Areas:  

Cancer

Pamvatamig (FUT8-KO) is an anti-EGFR/MET monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody.
loading...
    loading...
Cat. No.: HY-P99014A

Research Areas:  

Cancer

Cusatuzumab (FUT8-KO) is an anti-CD70 monoclonal antibody that prepared by knocking out the fucosyltransferase 8 gene (FUT8) to remove fucose and thereby enhance the ADCC activity of the antibody .
loading...
    loading...
Cat. No.: HY-P991514A

Target:  

CD20

Research Areas:  

Cancer

MIL62 (FUT8-KO) is a CD20-targeting antibody that prepared by knocking out the fucosyltransferase 8 gene (FUT8) to remove fucose and thereby enhance the ADCC activity of the antibody .
loading...
    loading...
Cat. No.: HY-P99226A
Daxdilimab (FUT8-KO) is an anti-ILT7 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.
loading...
    loading...
Cat. No.: HY-P990026A
Ulviprubart (FUT8-KO) is a humanized anti-KLRG1 monoclonal antibody lacking fucosyltransferase 8 (FUT8). Ulviprubart (FUT8-KO) can be used for the research of diseases such as inclusion body myositis (IBM) .
loading...
    loading...
Cat. No.: HY-P991481A

Target:  

CCR

Research Areas:  

Inflammation/Immunology Cancer

S-531011 (FUT8-KO) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody. S-531011 (FUT8-KO) can be used for the research of cancer immunity .
loading...
    loading...
Cat. No.: HY-P991944A

Target:  

CCR

Research Areas:  

Cancer

ZL-1218 (FUT8-KO) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody. ZL-1218 (FUT8-KO) can be used for the research of solid tumour .
loading...
    loading...
Cat. No.: HY-P99434A

Research Areas:  

Inflammation/Immunology

Amlitelimab (FUT8-KO) is Amlitelimab (HY-P99434) expressed in cells with the fucosyltransferase 8 gene (FUT8) knocked out. Amlitelimab (KY1005) is a monoclonal antibody (mAb) against OX40 ligand (OX40L). Amlitelimab inhibits the OX40-OX40L interaction and can be used for research on atopic dermatitis .
loading...
    loading...
Cat. No.: HY-P991135A
Synonyms: RO-7502175 (FUT8-KO); RG-6411 (FUT8-KO)

Target:  

CCR

Research Areas:  

Cancer

Enzelkitug (RO-7502175; RG-6411) (FUT8-KO) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody. Enzelkitug (FUT8-KO) can be used for the research of various solid tumors and hematological malignancies .
loading...
    loading...